Results 61 to 70 of about 5,788 (178)

Additional file 1: of Ionic liquid-based vortex-assisted DLLME followed by RP-LC-PDA method for bioassay of daclatasvir in rat serum: application to pharmacokinetics

, 2019
Figure S1. The schematic diagram showing the IL-DLLME process of daclatasvir from rat serum. Figure S2. The systematic predictable mechanism and its phase separation of IL from rat serum. Figure S3.
T. Rao (6648269), Marakada Sridevi (6648272), Challa Naidu (6648275), Bandaru Nagaraju (6648278)   +3 more
core   +1 more source

Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat

, 2017
Contains fulltext : 169944.pdf (Publisher’s version ) (Open Access)BACKGROUND: Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir.
Burger, D.M., Kanter, C.T.M.M. de, Smolders, E.J., Colbers, E.P.H., Velthoven-Graafland, K., Drenth, J.P.H., Smolders, E J, Colbers, E P H, de Kanter, C T M M, Burger, D M, Velthoven-Graafland, K, Drenth, J P H, Apotheek Klinische Farmacie   +12 more
core   +1 more source

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016 ...
Belaynew W. Taye, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex J. Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Y. Julian Rong, Marie Sinclair, Jacob George, William Sievert, Gerry MacQuillan, Edmund Tse, Amanda Wade, Wendy Cheng, Stuart K. Roberts, Paul J. Clark   +17 more
wiley   +1 more source

A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes

, 2016
Many direct-acting antiviral agents (DAAs) that selectively block hepatitis C virus (HCV) replication are currently under development. Among these agents is Daclatasvir, a first-in-class inhibitor targeting the NS5A viral protein. Although Daclatasvir is
Khaled H. Barakat (293854), Morris J. Robins (1651312), Anwar Anwar-Mohamed (1651315), Jack A. Tuszynski (160860), Michael Houghton (339213), D. Lorne Tyrrell (17808)   +5 more
core   +1 more source

Design and Synthesis of Novel Imidazo[4,5‐c]pyridine Derivatives, Evaluation of Their Activity Against Hepatitis C Virus and In Silico Prediction of Their Binding Mode to NS4B Protein

ChemMedChem, Volume 21, Issue 13, 14 July 2026.
A series of 18 novel imidazo[4,5‐c]pyridines was synthesized, and their anti‐HCV activity was evaluated. Compound 30b was identified as the most promising one, with EC50 = 6.61 µM. Molecular docking studies indicated the NS4B protein of the HCV as a potential target of these derivatives.
Eftychia Karampella, George Mpekoulis, Maria Georgiou, Iris Kolida, Katerina I. Kalliampakou, Eirini P. Kollia, Eleni V. Mikropoulou, Maria Halabalaki, Christos T. Chasapis, Niki Vassilaki, Nikolaos Lougiakis   +10 more
wiley   +1 more source

The safety of daclatasvir for the treatment of hepatitis C

, 2015
INTRODUCTION: The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against
Gordon, Stuart C, Jafri, Syed-Mohammed
core   +1 more source

IMPACT OF DIABETIC CONTROL ON ACHIEVING SUSTAINED VIROLOGIC RESPONSE IN CHRONIC HCV PATIENTS RECEIVING DIRECT-ACTING ANTIVIRALS [PDF]

Journal of the Egyptian Society of Parasitology, 2018
This study evaluated the effect of diabetic control on achieving sustained virologic response in patients with chronic hepatitis C virus infection who received direct-acting antivirals (Daclatasvir + Sofosbuvir ± Ribavirin). It included 100 patients with
AHMED MOHAMMED, AYMAN GAMIL, REHAM AL-SWAFF, KHALED ELKARMOUTY   +3 more
doaj   +1 more source

Engineered Metal–Organic Frameworks‐Based Materials for Environmental Detection

ENERGY &ENVIRONMENTAL MATERIALS, Volume 9, Issue 4, July 2026.
Engineered metal–organic frameworks (MOFs) regulated by various material modification strategies are discussed for environmental contaminant detection under different sensing mechanisms, providing future improvements of MOFs in environmental detection. Sensitive and selective detection of contaminants is crucial for environmental protection.
Pan Gao, Song Wang, Yuechao Yao, Yibo Dou   +3 more
wiley   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis

Gut and Liver, 2019
Background/Aims We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods : We performed a single-arm, multicenter prospective study.
Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song   +11 more
doaj   +1 more source